Nanovesicle aerosols as surfactant therapy in lung injury

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 5, 2012, Pages 665-672

  Kaviratna, Anubhav S ^a   Banerjee, R ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Acute lung injury; Airway patency; Nanovesicles; Surfactant therapy

Indexed keywords

ACUTE LUNG INJURY; BRONCHOALVEOLAR LAVAGE FLUID; DIPALMITOYL PHOSPHATIDYLCHOLINE; INTRATRACHEAL; LUNG INJURY; NANOVESICLE; NANOVESICLES; PHOSPHATIDYLETHANOLAMINE; PROTEIN LEAKAGES; PULMONARY SURFACTANTS;

ATMOSPHERIC AEROSOLS; PHOSPHOLIPIDS; SURFACE ACTIVE AGENTS;

BIOLOGICAL ORGANS;

ALBUMIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; FIBRINOGEN; LUNG SURFACTANT; PHOSPHOLIPID;

ACUTE LUNG INJURY; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG LAVAGE; MOUSE; NONHUMAN; SERUM;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ACUTE LUNG INJURY; AEROSOLS; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; MICE; NANOPARTICLES; PHOSPHATIDYLETHANOLAMINES; SURFACE-ACTIVE AGENTS;

MUS;

EID: 84862680166     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.08.004     Document Type: Article

References (23)

1. Enhorning G., Hohlfeld J., Krug N., Lema G., Welliver R.C. Surfactant function affected by airway inflammation and cooling: possible impact on exercise-induced asthma. Eur Respir J 2000, 15:532-538.
2. Ellyett K.M., Cragg P.A., Broadbent R.S. Effect of surfactant deficiency and surfactant replacement on airway patency in the piglet lung. Respir Physiol Neurobiol 2006, 150:173-181.
3. Enhorning G. Surfactant in airway disease. Chest 2008, 133:975-980.
4. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999, 13:1455-1476.
5. Nishina K., Mikawa K., Takao Y., Maekawa N., Obara H. Effects of exogenous surfactant on acute lung injury induced by intratracheal instillation of infant formula or human breast milk in rabbits. Anesthesiology 1999, 91:240-252.
6. Eijking E.P., Gommers D., So K.L., Moniek P.M., Mouton J.W., Lachmann B. Prevention of respiratory failure after hydrochloric acid aspiration by intratracheal surfactant instillation in rats. Anesth Analg 1993, 76:472-477.
7. Nag K., Hillier A., Parsons K., Garcia M.F. Interactions of serum with lung surfactant extract in the bronchiolar and alveolar airway models. Respir Physiol Neurobiol 2007, 157:411-424.
8. Fuchimukai T., Fujiwara T., Takahashi A., Enhorning G. Artificial pulmonary surfactant inhibited by proteins. J Appl Physiol 1987, 62:429-437.
9. Fattal E., Dubernet C. ''Smart'' delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 2004, 56:931-946.
10. Egerdie B., Singer M. Morphology of gel state phosphatidylethanolamine and phosphatidylcholine liposomes: a negative stain electron microscopic study. Chem Phys Lipids 1982, 31:75-85.
11. Zhang J., Chen X.G., Peng W.B., Liu C.S. Uptake of oleoyl-chitosan nanoparticles by A549 cells. Nanomed Nanotechnol Biol Med 2008, 4:208-214.
12. Bergstrand N., Arfvidsson M.C., Edwards K. Interactions between pH-sensitive liposomes and model membranes. Biophys Chem 2003, 104:361-379.
13. Stearns R.C., Paulauskis J.D., Godleski J.J. Endocytosis of ultrafine particles by A549 cells. Am J Resp Cell Mol Biol 2001, 24:108-115.
14. Weiser M.R., Pechet T.T.V., Williams J.P., Ma M., Frenette P.S., Moore F.D. Experimental murine acid aspiration injury is mediated by neutrophils and the alternative complement pathway. J Appl Physiol 1997, 83:1090-1095.
15. Schram V., Hall S.B. Thermodynamic effects of the hydrophobic surfactant proteins on the early adsorption of pulmonary surfactant. Biophys J 2001, l81:1536-1546.
16. Perez Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 2008, 1779:1676-1695.
17. Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev 2001, 53:307-319.
18. Foster K.A., Oster C.G., Mayer M.M., Avery M.L., Audus K.L. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998, 243:359-366.
19. Nag K., Munro J.G., Hearn S.A., Rasmusson J., Petersen N.O., Possmayer F. Correlated atomic force and transmission electron microscopy of nanotubular structures in pulmonary surfactant. J Struct Biol 1999, 126:1-15.
20. Kaviratna A., Shah A.R., Rao S.S., Banerjee R. Pulmonary surfactant nanostructures and their implications. Dynamic Biochem Process Biotechnol Mol Biol 2009, 2:21-32.
21. Bosquillon C., Lombry C., Pr'eat V., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 2001, 70:329-339.
22. Jones B.G., Dickinson P.A., Gumbleton M., Kellaway I.W. The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages. Int J Pharm 2002, 236:65-79.
23. Tomod K., Makino K. Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres. Colloids Surfaces B: Biointerfaces 2007, 55:115-124.